Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Insights and Forecast to 2027

SKU ID : QYR-18238097 | Publishing Date : 13-May-2021 | No. of pages : 112

Detailed TOC of Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Insights and Forecast to 2027

1 Study Coverage
    1.1 VPM1002 (Tuberculosis BCG Based Vaccine) Product Introduction
    1.2 Market by Type
        1.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size Growth Rate by Type
        1.4.2 0.5ml Package
        1.4.3 1ml Package
        1.2.4 2ml Package
        1.2.5 Other
    1.3 Market by Application
        1.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size Growth Rate by Application
        1.3.2 0-5 Years Old
        1.3.3 5-18 Years Old
        1.3.4 18-45 Years Old
        1.3.5 45-65 Years Old
        1.3.6 ≥65 Years Old
    1.4 Study Objectives
    1.5 Years Considered

2 Executive Summary
    2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Estimates and Forecasts 2016-2027
    2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Estimates and Forecasts 2016-2027
    2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region: 2016 VS 2021 VS 2027
    2.4 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Regions by Sales
        2.4.1 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Regions by Sales (2016-2021)
        2.4.2 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Regions by Sales (2022-2027)
    2.5 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Regions by Revenue
        2.5.1 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Regions by Revenue (2016-2021)
        2.5.2 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Regions by Revenue (2022-2027)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Manufacturers
        3.1.1 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Manufacturers by Sales (2016-2021)
        3.1.2 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Manufacturers Market Share by Sales (2016-2021)
        3.1.3 Global Top 10 and Top 5 Companies by VPM1002 (Tuberculosis BCG Based Vaccine) Sales in 2020
    3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Manufacturers
        3.2.1 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Manufacturers by Revenue (2016-2021)
        3.2.2 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Manufacturers Market Share by Revenue (2016-2021)
        3.2.3 Global Top 10 and Top 5 Companies by VPM1002 (Tuberculosis BCG Based Vaccine) Revenue in 2020
    3.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Price by Manufacturers
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
    4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type
        4.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Historical Sales by Type (2016-2021)
        4.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Forecasted Sales by Type (2022-2027)
        4.1.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2016-2027)
    4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type
        4.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Historical Revenue by Type (2016-2021)
        4.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Forecasted Revenue by Type (2022-2027)
        4.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2016-2027)
    4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Price by Type
        4.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Price by Type (2016-2021)
        4.3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Price Forecast by Type (2022-2027)
5 Market Size by Application
    5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application
        5.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Historical Sales by Application (2016-2021)
        5.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Forecasted Sales by Application (2022-2027)
        5.1.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2016-2027)
    5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application
        5.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Historical Revenue by Application (2016-2021)
        5.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Forecasted Revenue by Application (2022-2027)
        5.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2016-2027)
    5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Price by Application
        5.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Price by Application (2016-2021)
        5.3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Price Forecast by Application (2022-2027)

6 North America
    6.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type
        6.1.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2027)
        6.1.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2027)
    6.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application
        6.2.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2027)
        6.2.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2027)
    6.3 North America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country
        6.3.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2016-2027)
        6.3.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2016-2027)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type
        7.1.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2017-2027)
        7.1.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2017-2027)
    7.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application
        7.2.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2017-2027)
        7.2.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2017-2027)
    7.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country
        7.3.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2017-2027)
        7.3.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2017-2027)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type
        8.1.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2018-2027)
        8.1.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2018-2027)
    8.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application
        8.2.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2018-2027)
        8.2.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2018-2027)
    8.3 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Region
        8.3.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2018-2027)
        8.3.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2018-2027)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type
        9.1.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2019-2027)
        9.1.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2019-2027)
    9.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application
        9.2.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2019-2027)
        9.2.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2019-2027)
    9.3 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country
        9.3.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2019-2027)
        9.3.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2019-2027)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
6 Middle East and Africa
    6.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type
        6.1.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2027)
        6.1.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2027)
    6.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application
        6.2.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2027)
        6.2.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2027)
    6.3 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country
        6.3.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2016-2027)
        6.3.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2016-2027)
        6.3.3 Turkey
        6.3.4 Saudi Arabia
        6.3.5 UAE

11 Company Profiles
    11.1 Vakzine Projekt Management (VPM)
        11.1.1 Vakzine Projekt Management (VPM) Corporation Information
        11.1.2 Vakzine Projekt Management (VPM) Overview
        11.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Sales, Price, Revenue and Gross Margin (2016-2021)
        11.1.4 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Product Description
        11.1.5 Vakzine Projekt Management (VPM) Related Developments
    11.2 Serum Institute of India
        11.2.1 Serum Institute of India Corporation Information
        11.2.2 Serum Institute of India Overview
        11.2.3 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Sales, Price, Revenue and Gross Margin (2016-2021)
        11.2.4 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Product Description
        11.2.5 Serum Institute of India Related Developments
    11.1 Vakzine Projekt Management (VPM)
        11.1.1 Vakzine Projekt Management (VPM) Corporation Information
        11.1.2 Vakzine Projekt Management (VPM) Overview
        11.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Sales, Price, Revenue and Gross Margin (2016-2021)
        11.1.4 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Product Description
        11.1.5 Vakzine Projekt Management (VPM) Related Developments

12 Value Chain and Sales Channels Analysis
    12.1 VPM1002 (Tuberculosis BCG Based Vaccine) Value Chain Analysis
    12.2 VPM1002 (Tuberculosis BCG Based Vaccine) Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 VPM1002 (Tuberculosis BCG Based Vaccine) Production Mode & Process
    12.4 VPM1002 (Tuberculosis BCG Based Vaccine) Sales and Marketing
        12.4.1 VPM1002 (Tuberculosis BCG Based Vaccine) Sales Channels
        12.4.2 VPM1002 (Tuberculosis BCG Based Vaccine) Distributors
    12.5 VPM1002 (Tuberculosis BCG Based Vaccine) Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 VPM1002 (Tuberculosis BCG Based Vaccine) Industry Trends
    13.2 VPM1002 (Tuberculosis BCG Based Vaccine) Market Drivers
    13.3 VPM1002 (Tuberculosis BCG Based Vaccine) Market Challenges
    13.4 VPM1002 (Tuberculosis BCG Based Vaccine) Market Restraints

14 Key Findings in The Global VPM1002 (Tuberculosis BCG Based Vaccine) Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Figures, Tables and Charts Available in Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Insights and Forecast to 2027

List of Tables
    Table 1. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
    Table 2. Major Manufacturers of 0.5ml Package
    Table 3. Major Manufacturers of 1ml Package
    Table 4. Major Manufacturers of 2ml Package
    Table 5. Major Manufacturers of Other
    Table 6. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
    Table 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
    Table 8. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2016-2021) & (K Doses)
    Table 9. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Region (2016-2021)
    Table 10. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2016-2021) & (K Doses)
    Table 11. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Region (2022-2027)
    Table 12. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2016-2021) & (US$ Million)
    Table 13. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Region (2016-2021)
    Table 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2022-2027) & (US$ Million)
    Table 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Region (2022-2027)
    Table 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Manufacturers (2016-2021) & (K Doses)
    Table 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Manufacturers (2016-2021)
    Table 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Manufacturers (2016-2021) & (US$ Million)
    Table 19. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Manufacturers (2016-2021)
    Table 20. VPM1002 (Tuberculosis BCG Based Vaccine) Price by Manufacturers 2016-2021 (USD/Dose)
    Table 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global VPM1002 (Tuberculosis BCG Based Vaccine) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VPM1002 (Tuberculosis BCG Based Vaccine) as of 2020)
    Table 23. VPM1002 (Tuberculosis BCG Based Vaccine) Manufacturing Base Distribution and Headquarters
    Table 24. Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) Product Offered
    Table 25. Date of Manufacturers Enter into VPM1002 (Tuberculosis BCG Based Vaccine) Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2021) & (K Doses)
    Table 28. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2022-2027) & (K Doses)
    Table 29. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Type (2016-2021)
    Table 30. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Type (2022-2027)
    Table 31. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2021) & (US$ Million)
    Table 32. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2022-2027) & (US$ Million)
    Table 33. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Type (2016-2021)
    Table 34. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Type (2022-2027)
    Table 35. VPM1002 (Tuberculosis BCG Based Vaccine) Price by Type (2016-2021) & (USD/Dose)
    Table 36. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price Forecast by Type (2022-2027) & (USD/Dose)
    Table 37. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2021) & (K Doses)
    Table 38. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2022-2027) & (K Doses)
    Table 39. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Application (2016-2021)
    Table 40. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Application (2022-2027)
    Table 41. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2021) & (US$ Million)
    Table 42. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2022-2027) & (US$ Million)
    Table 43. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Application (2016-2021)
    Table 44. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Application (2022-2027)
    Table 45. VPM1002 (Tuberculosis BCG Based Vaccine) Price by Application (2016-2021) & (USD/Dose)
    Table 46. Global VPM1002 (Tuberculosis BCG Based Vaccine) Price Forecast by Application (2022-2027) & (USD/Dose)
    Table 47. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2021) & (K Doses)
    Table 48. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2022-2027) & (K Doses)
    Table 49. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2021) & (US$ Million)
    Table 50. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2022-2027) & (US$ Million)
    Table 51. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2021) & (K Doses)
    Table 52. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2022-2027) & (K Doses)
    Table 53. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2021) & (US$ Million)
    Table 54. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2022-2027) & (US$ Million)
    Table 55. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2016-2021) & (K Doses)
    Table 56. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2022-2027) & (K Doses)
    Table 57. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2016-2021) & (US$ Million)
    Table 58. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2022-2027) & (US$ Million)
    Table 59. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2021) & (K Doses)
    Table 60. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2022-2027) & (K Doses)
    Table 61. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2021) & (US$ Million)
    Table 62. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2022-2027) & (US$ Million)
    Table 63. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2021) & (K Doses)
    Table 64. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2022-2027) & (K Doses)
    Table 65. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2021) & (US$ Million)
    Table 66. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2022-2027) & (US$ Million)
    Table 67. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2016-2021) & (K Doses)
    Table 68. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2022-2027) & (K Doses)
    Table 69. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2016-2021) & (US$ Million)
    Table 70. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2022-2027) & (US$ Million)
    Table 71. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2021) & (K Doses)
    Table 72. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2022-2027) & (K Doses)
    Table 73. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2021) & (US$ Million)
    Table 74. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2022-2027) & (US$ Million)
    Table 75. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2021) & (K Doses)
    Table 76. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2022-2027) & (K Doses)
    Table 77. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2021) & (US$ Million)
    Table 78. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2022-2027) & (US$ Million)
    Table 79. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2016-2021) & (K Doses)
    Table 80. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Region (2022-2027) & (K Doses)
    Table 81. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2016-2021) & (US$ Million)
    Table 82. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Region (2022-2027) & (US$ Million)
    Table 83. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2021) & (K Doses)
    Table 84. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2022-2027) & (K Doses)
    Table 85. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2021) & (US$ Million)
    Table 86. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2022-2027) & (US$ Million)
    Table 87. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2021) & (K Doses)
    Table 88. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2022-2027) & (K Doses)
    Table 89. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2021) & (US$ Million)
    Table 90. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2022-2027) & (US$ Million)
    Table 91. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2016-2021) & (K Doses)
    Table 92. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2022-2027) & (K Doses)
    Table 93. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2016-2021) & (US$ Million)
    Table 94. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2022-2027) & (US$ Million)
    Table 95. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2021) & (K Doses)
    Table 96. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2022-2027) & (K Doses)
    Table 97. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2021) & (US$ Million)
    Table 98. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2022-2027) & (US$ Million)
    Table 99. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2021) & (K Doses)
    Table 100. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2022-2027) & (K Doses)
    Table 101. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2021) & (US$ Million)
    Table 102. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2022-2027) & (US$ Million)
    Table 103. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2016-2021) & (K Doses)
    Table 104. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2022-2027) & (K Doses)
    Table 105. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2016-2021) & (US$ Million)
    Table 106. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2022-2027) & (US$ Million)
    Table 107. Vakzine Projekt Management (VPM) Corporation Information
    Table 108. Vakzine Projekt Management (VPM) Description and Major Businesses
    Table 109. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
    Table 110. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Product
    Table 111. Vakzine Projekt Management (VPM) Recent Developments
    Table 112. Serum Institute of India Corporation Information
    Table 113. Serum Institute of India Description and Major Businesses
    Table 114. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
    Table 115. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Product
    Table 116. Serum Institute of India Recent Developments
    Table 117. Key Raw Materials Lists
    Table 118. Raw Materials Key Suppliers Lists
    Table 119. VPM1002 (Tuberculosis BCG Based Vaccine) Distributors List
    Table 120. VPM1002 (Tuberculosis BCG Based Vaccine) Customers List
    Table 121. VPM1002 (Tuberculosis BCG Based Vaccine) Market Trends
    Table 122. VPM1002 (Tuberculosis BCG Based Vaccine) Market Drivers
    Table 123. VPM1002 (Tuberculosis BCG Based Vaccine) Market Challenges
    Table 124. VPM1002 (Tuberculosis BCG Based Vaccine) Market Restraints
    Table 125. Research Programs/Design for This Report
    Table 126. Key Data Information from Secondary Sources
    Table 127. Key Data Information from Primary Sources
List of Figures
    Figure 1. VPM1002 (Tuberculosis BCG Based Vaccine) Product Picture
    Figure 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Type in 2020 & 2027
    Figure 3. 0.5ml Package Product Picture
    Figure 4. 1ml Package Product Picture
    Figure 5. 2ml Package Product Picture
    Figure 6. Other Product Picture
    Figure 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application in 2020 & 2027
    Figure 8. 0-5 Years Old
    Figure 9. 5-18 Years Old
    Figure 10. 18-45 Years Old
    Figure 11. 45-65 Years Old
    Figure 12. ≥65 Years Old
    Figure 13. VPM1002 (Tuberculosis BCG Based Vaccine) Report Years Considered
    Figure 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales 2016-2027 (K Doses)
    Figure 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue, (US$ Million), 2016 VS 2021 VS 2027
    Figure 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue 2016-2027 (US$ Million)
    Figure 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Region in Percentage: 2020 Versus 2027
    Figure 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Region (2016-2021)
    Figure 19. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Region (2022-2027)
    Figure 20. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales YoY (2016-2027) & (K Doses)
    Figure 21. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue YoY (2016-2027) & (US$ Million)
    Figure 22. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales YoY (2016-2027) & (K Doses)
    Figure 23. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue YoY (2016-2027) & (US$ Million)
    Figure 24. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales YoY (2016-2027) & (K Doses)
    Figure 25. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue YoY (2016-2027) & (US$ Million)
    Figure 26. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales YoY (2016-2027) & (K Doses)
    Figure 27. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue YoY (2016-2027) & (US$ Million)
    Figure 28. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales YoY (2016-2027) & (K Doses)
    Figure 29. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue YoY (2016-2027) & (US$ Million)
    Figure 30. The Top 10 and Top 5 Players Market Share by VPM1002 (Tuberculosis BCG Based Vaccine) Sales in 2020
    Figure 31. The Top 10 and Top 5 Players Market Share by VPM1002 (Tuberculosis BCG Based Vaccine) Revenue in 2020
    Figure 32. VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
    Figure 33. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2016-2027)
    Figure 34. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2016-2027)
    Figure 35. Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2016-2027)
    Figure 36. Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2016-2027)
    Figure 37. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2016-2027)
    Figure 38. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2016-2027)
    Figure 39. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2016-2027)
    Figure 40. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2016-2027)
    Figure 41. North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Country (2016-2027)
    Figure 42. North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Country (2016-2027)
    Figure 43. U.S. VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 44. Canada VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 45. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2016-2027)
    Figure 46. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2016-2027)
    Figure 47. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2016-2027)
    Figure 48. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2016-2027)
    Figure 49. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Country (2016-2027)
    Figure 50. Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Country (2016-2027)
    Figure 51. Germany VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 52. France VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 53. U.K. VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 54. Italy VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 55. Russia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 56. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2016-2027)
    Figure 57. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2016-2027)
    Figure 58. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2016-2027)
    Figure 59. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2016-2027)
    Figure 60. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Region (2016-2027)
    Figure 61. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Region (2016-2027)
    Figure 62. China VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 63. Japan VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 64. South Korea VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 65. India VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 66. Australia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 67. Taiwan VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 68. Indonesia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 69. Thailand VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 70. Malaysia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 71. Philippines VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 72. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2016-2027)
    Figure 73. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2016-2027)
    Figure 74. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2016-2027)
    Figure 75. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2016-2027)
    Figure 76. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Country (2016-2027)
    Figure 77. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Country (2016-2027)
    Figure 78. Mexico VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 79. Brazil VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 80. Argentina VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 81. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2016-2027)
    Figure 82. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2016-2027)
    Figure 83. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2016-2027)
    Figure 84. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2016-2027)
    Figure 85. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales Share by Country (2016-2027)
    Figure 86. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Country (2016-2027)
    Figure 87. Turkey VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 88. Saudi Arabia VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 89. UAE VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027) & (US$ Million)
    Figure 90. VPM1002 (Tuberculosis BCG Based Vaccine) Value Chain
    Figure 91. VPM1002 (Tuberculosis BCG Based Vaccine) Production Process
    Figure 92. Channels of Distribution
    Figure 93. Distributors Profiles
    Figure 94. Bottom-up and Top-down Approaches for This Report
    Figure 95. Data Triangulation
    Figure 96. Key Executives Interviewed

Keyplayers in Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Insights and Forecast to 2027

Vakzine Projekt Management (VPM)
Serum Institute of India

Request Sample

Pre-order Enquiry

Request Discount

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Insights and Forecast to 2027

Detailed TOC of Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Insights and Forecast to 2027

List of Figures, Tables and Charts Available in Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Insights and Forecast to 2027

Keyplayers in Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Insights and Forecast to 2027

Our Clients